Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 22.9% during mid-day trading on Friday . The stock traded as low as C$0.18 and last traded at C$0.19. 504,239 shares traded hands during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Trading Down 22.9 %
The company has a market capitalization of C$26.96 million, a PE ratio of -5.39 and a beta of 0.20. The company’s fifty day moving average is C$0.19 and its 200-day moving average is C$0.11. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Vertiv Stock Under Pressure: Is Opportunity Knocking?
- Consumer Staples Stocks, Explained
- MicroStrategy’s 8% Preferred Stock: What Investors Should Know
- Short Selling: How to Short a Stock
- Biotechs on the Brink: 2 Stocks With Huge Potential
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
